Streetbeat News

Analyst Ratings

ASLE

Truist Securities analyst Michael Ciarmoli has maintained a Buy rating on AerSale (NASDAQ:ASLE) but lowered the price target from $19 to $12.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 2:43 pm

LXU

RBC Capital analyst Andrew Wong maintains an Outperform rating on LSB Industries (NYSE:LXU) but lowers the price target from $12 to $10.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 2:40 pm

IMRX

Needham analyst Ami Fadia reiterated a Buy rating on Immuneering (NASDAQ:IMRX) and maintained a $20 price target.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 2:39 pm

ASML

GSK

RSP

Goldman Sachs highlights concerns over the U.S. stock market's heavy concentration in its largest tech stocks, suggesting a 'barbell approach' for investors to diversify. The top 10 U.S. stocks now represent 33% of the S&P 500 market cap, leading to market performance skew. The firm also sees investment opportunities in Japan and the healthcare sector, and highlights European GRANOLAS stocks for their lower valuations and solid performance.

Portfolio Pulse from Piero Cingari

March 11, 2024 | 2:38 pm

ATNM

HC Wainwright & Co. analyst Joseph Pantginis maintains a Buy rating on Actinium Pharma (ATNM) with a maintained price target of $50.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 2:38 pm

PROF

Alliance Global Partners analyst Ben Haynor maintains a Buy rating on Profound Medical (NASDAQ:PROF) but lowers the price target from $12.75 to $10.8.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 2:33 pm

MNKD

MannKind Corporation (NASDAQ:MNKD) shares are in focus due to initial meal challenge data from INHALE-3, a Phase 4 clinical trial for inhaled insulin, showing promising results. The company also reported Q4 earnings of 2 cents per share with sales of $58.47 million, surpassing analyst estimates. CNBC's Jim Cramer discussed the stock, noting its potential for an earnings breakout. Analysts have a 12-month price target range of $6.50 to $7.50, with an average of $7.00. MannKind shares are currently down 8.35% at $4.82.

Portfolio Pulse from Erica Kollmann

March 11, 2024 | 2:28 pm

FNV

RBC Capital analyst Josh Wolfson reiterated a 'Sector Perform' rating on Franco-Nevada (NYSE:FNV) and maintained a price target of $135.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 2:28 pm